Parametric Portfolio Associates LLC cut its holdings in Loxo Oncology, Inc. (NASDAQ:LOXO) by 14.1% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 32,379 shares of the biopharmaceutical company’s stock after selling 5,300 shares during the period. Parametric Portfolio Associates LLC owned approximately 0.12% of Loxo Oncology worth $2,596,000 at the end of the most recent reporting period.

A number of other institutional investors have also bought and sold shares of the business. Legal & General Group Plc lifted its stake in Loxo Oncology by 8.4% in the first quarter. Legal & General Group Plc now owns 3,682 shares of the biopharmaceutical company’s stock worth $154,000 after purchasing an additional 284 shares during the last quarter. Wells Fargo & Company MN lifted its stake in Loxo Oncology by 3.8% in the second quarter. Wells Fargo & Company MN now owns 16,095 shares of the biopharmaceutical company’s stock worth $1,291,000 after purchasing an additional 592 shares during the last quarter. Alps Advisors Inc. lifted its stake in Loxo Oncology by 7.4% in the second quarter. Alps Advisors Inc. now owns 23,601 shares of the biopharmaceutical company’s stock worth $1,893,000 after purchasing an additional 1,623 shares during the last quarter. ProShare Advisors LLC lifted its stake in Loxo Oncology by 13.2% in the second quarter. ProShare Advisors LLC now owns 15,192 shares of the biopharmaceutical company’s stock worth $1,218,000 after purchasing an additional 1,767 shares during the last quarter. Finally, Goldman Sachs Group Inc. lifted its stake in Loxo Oncology by 4.9% in the first quarter. Goldman Sachs Group Inc. now owns 44,178 shares of the biopharmaceutical company’s stock worth $1,860,000 after purchasing an additional 2,045 shares during the last quarter.

Several analysts have weighed in on the stock. BTIG Research reissued a “buy” rating and issued a $102.00 price target (up from $75.00) on shares of Loxo Oncology in a research note on Friday, September 29th. Cowen and Company reissued a “buy” rating on shares of Loxo Oncology in a research note on Thursday, September 28th. Morgan Stanley reissued an “overweight” rating and issued a $103.00 price target (up from $95.00) on shares of Loxo Oncology in a research note on Friday, October 6th. Citigroup Inc. reissued a “buy” rating and issued a $112.00 price target (up from $86.00) on shares of Loxo Oncology in a research note on Friday, October 20th. Finally, JMP Securities downgraded shares of Loxo Oncology from an “outperform” rating to a “market perform” rating and lowered their price target for the stock from $83.12 to $17.14 in a research note on Tuesday, August 29th. They noted that the move was a valuation call. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $80.02.

In other news, CEO Joshua H. Bilenker sold 15,000 shares of the company’s stock in a transaction dated Tuesday, August 15th. The shares were sold at an average price of $73.56, for a total transaction of $1,103,400.00. Following the completion of the transaction, the chief executive officer now directly owns 196,207 shares of the company’s stock, valued at $14,432,986.92. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Naarden Jacob Van sold 3,082 shares of the company’s stock in a transaction dated Tuesday, August 15th. The shares were sold at an average price of $73.57, for a total transaction of $226,742.74. Following the transaction, the insider now directly owns 1,541 shares of the company’s stock, valued at $113,371.37. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 100,637 shares of company stock valued at $8,245,787. Insiders own 27.80% of the company’s stock.

Loxo Oncology, Inc. (LOXO) opened at $87.79 on Monday. Loxo Oncology, Inc. has a one year low of $17.34 and a one year high of $95.92.

Loxo Oncology (NASDAQ:LOXO) last issued its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($1.14) EPS for the quarter, missing the consensus estimate of ($0.99) by ($0.15). During the same quarter in the previous year, the company earned ($0.77) EPS. analysts expect that Loxo Oncology, Inc. will post -4.41 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This report was first published by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another website, it was copied illegally and reposted in violation of U.S. and international copyright and trademark law. The original version of this report can be read at https://www.watchlistnews.com/parametric-portfolio-associates-llc-sells-5300-shares-of-loxo-oncology-inc-loxo/1682191.html.

About Loxo Oncology

Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.

Institutional Ownership by Quarter for Loxo Oncology (NASDAQ:LOXO)

Receive News & Ratings for Loxo Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.